RPS7A Antibody

What is RPS7 and what molecular characteristics should researchers know?

RPS7 (ribosomal protein S7) is a component of the 40S ribosomal subunit that may also be known by alternative nomenclature including DBA8, eS7, 40S ribosomal protein S7, and small ribosomal subunit protein eS7. Structurally, the protein has a molecular weight of approximately 22.1 kilodaltons. The protein is highly conserved, with orthologs present across diverse species including plants, flies, canines, porcine models, primates, and rodents (mouse and rat models) . Understanding these characteristics is essential for proper experimental design and antibody selection.

What applications are RPS7A antibodies validated for in research?

RPS7A antibodies have been validated for multiple research applications including:

• Western Blotting (WB)

• Immunocytochemistry (ICC)

• Immunohistochemistry (IHC-p)

• Flow Cytometry (FCM)

• RNA Immunoprecipitation (RIP)

For optimal results in each application, researchers should select antibodies specifically validated for their intended experimental approach. For instance, when performing RNA immunoprecipitation assays to study RNA-protein interactions, researchers have successfully used anti-RPS7 antibodies to immunoprecipitate RPS7-bound RNA complexes from cell lysates, followed by qRT-PCR detection of the associated transcripts .

How should researchers validate RPS7A antibody specificity?

Thorough validation is critical for reliable RPS7A antibody-based experiments. Recommended approaches include:

• Positive and negative controls: Use cell lines or tissues with known RPS7 expression levels. CRISPR-Cas9 knockout models of RPS7 provide excellent negative controls.

• Multiple antibody comparison: Utilize antibodies from different suppliers or those recognizing different epitopes to confirm specificity.

• Knockdown validation: Compare staining patterns between wild-type cells and those with RPS7 knockdown (siRNA or shRNA).

• Cross-reactivity testing: Particularly important when studying RPS7 orthologs in multiple species or when distinguishing between RPS7A and RPS7B isoforms.

Research indicates that antibodies targeting specific regions of RPS7 can effectively distinguish between ubiquitinated and non-ubiquitinated forms of the protein, which is crucial for studying its post-translational modifications .

How can researchers effectively use RPS7A antibodies for RNA immunoprecipitation studies?

RNA immunoprecipitation (RIP) with RPS7A antibodies requires careful optimization to identify RNA binding partners. A methodological approach based on recent publications:

• Cross-linking: Prior to cell lysis, perform formaldehyde cross-linking (1% for 10 minutes at room temperature) to stabilize RNA-protein interactions.

• Optimized lysis buffer: Use a buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% NP-40, with RNase and protease inhibitors.

• Pre-clearing: Pre-clear lysates with protein A/G beads to reduce background.

• Antibody incubation: Incubate pre-cleared lysates with RPS7 antibody (typically 5-10 μg) overnight at 4°C.

• RNA extraction and analysis: After washing, extract RNA from immunoprecipitates and analyze by qRT-PCR or RNA-seq.

This approach has been successfully employed to demonstrate that RPS7 binds to LOXL2 mRNA at AUUUA motifs in the 3155-3375 region of the 3'UTR, contributing to mRNA stabilization .

What approaches can differentiate extra-ribosomal functions of RPS7 from its canonical role?

Distinguishing extra-ribosomal functions requires specialized experimental designs:

• Subcellular fractionation: Separate cytoplasmic, nuclear, and ribosome-associated fractions before RPS7 detection to identify non-ribosomal pools of the protein.

• Mutation analysis: Generate RPS7 mutants that retain ribosomal binding but lose specific extra-ribosomal interactions, or vice versa.

• Proximity labeling: Use BioID or APEX2 fusions with RPS7 to identify proximity partners in different cellular compartments.

• Synchronized cells: Analyze RPS7 interactions during different cell cycle phases when ribosome biogenesis varies.

These approaches have revealed that beyond its canonical role in the ribosome, RPS7 functions as an RNA-binding protein that regulates mRNA stability of specific targets like LOXL2, thereby influencing cancer progression pathways independently of its ribosomal function .

How does ubiquitination of RPS7/eS7A regulate mRNA quality control pathways?

RPS7/eS7A ubiquitination represents a critical regulatory mechanism in mRNA quality control:

• Sequential modification: RPS7/eS7A undergoes a step-wise ubiquitination process involving:

  • Initial monoubiquitination by the E3 ligase Not4

  • Subsequent K63-linked polyubiquitination mediated by Hel2

• Specific lysine residues: Key ubiquitination sites include K72, K76, K83, and K84, with K83 and K84 being particularly important for NGD (No-Go Decay) pathways .

• Functional consequences: Ubiquitination of RPS7/eS7A plays a crucial role in:

  • Endonucleolytic cleavage in NGD RQC− (Ribosome Quality Control) pathway

  • Recruitment of mRNA decay factors

  • Resolution of ribosome collision events

Experiments with eS7A-4KR mutants (where key lysine residues are replaced with arginine) show significantly decreased NGD efficiency, confirming the essential role of these modifications in mRNA surveillance mechanisms .

What is the relationship between RPS7 and ribosome collision detection?

RPS7 plays a pivotal role in detecting ribosome collisions, which serve as signals for translation quality control:

• Collision interface: When ribosomes collide during translation, RPS7 forms part of a unique structural interface that becomes accessible to quality control factors.

• Signal amplification: Ubiquitination of RPS7 at the collision interface serves as a signal amplification mechanism that recruits downstream quality control factors.

• Disome formation: At least two adjacent ribosomes (a disome unit) rather than a single stalled 80S ribosome serve as a minimal control hub where RQC and NGD are induced after translation arrest .

• Response to translation inhibitors: Treatment with translation elongation inhibitors like anisomycin increases ribosome collisions, enhancing RPS7-dependent quality control mechanisms .

Research demonstrates that cells with defective RPS7 ubiquitination pathways show increased sensitivity to translation inhibitors, highlighting the protective function of this quality control mechanism .

How does RPS7 contribute to hepatocellular carcinoma progression?

RPS7 has been identified as a pro-oncogenic factor in hepatocellular carcinoma (HCC) through several mechanisms:

• Upregulation in metastatic HCC: RNA-seq analysis of primary HCC tissues revealed that RPS7 expression is significantly increased in tissues with extrahepatic metastasis compared to metastasis-free HCC tissues .

• Promotion of metastatic phenotypes: Gain- and loss-of-function studies demonstrated that RPS7 enhances:

  • Cell adhesion

  • Migration and invasion capabilities

  • Lung metastasis in animal models

• LOXL2 mRNA stabilization: Mechanistically, RPS7 binds to AUUUA motifs in the 3'UTR of LOXL2 mRNA, increasing its stability and expression .

• ITGB1-FAK-SRC pathway activation: The elevated LOXL2 levels maintain ITGB1 protein stability, activating downstream FAK/SRC signaling and accelerating focal adhesion formation, which contributes to metastasis .

What explains RPS7's context-dependent roles across different cancer types?

RPS7 exhibits dual functionality in cancer biology, acting as:

• Tumor suppressor in:

  • Colorectal cancer

  • Ovarian tumors

• Pro-oncogenic factor in:

  • Prostate cancer

  • Lung adenocarcinoma

  • Breast cancer

  • Hepatocellular carcinoma

This context-dependency likely results from:

• Tissue-specific binding partners: Different interaction networks in various tissues alter RPS7 function.

• Alternative post-translational modifications: Varying ubiquitination patterns may direct RPS7 toward different functions.

• Subcellular localization differences: Nuclear versus cytoplasmic distribution may determine which pathways RPS7 impacts.

• Target RNA repertoire: The collection of mRNAs that RPS7 stabilizes is likely tissue-specific, leading to different downstream effects.

What are the optimal conditions for RPS7A antibody-based Western blotting?

For successful Western blot detection of RPS7A:

• Sample preparation:

  • For total RPS7 detection: Standard RIPA buffer with protease inhibitors

  • For ubiquitinated forms: Include deubiquitinase inhibitors (e.g., PR-619, 10-20 μM)

• Gel separation:

  • 12-15% SDS-PAGE gels provide optimal resolution for the ~22 kDa RPS7 protein

  • 8-10% gels better visualize higher molecular weight ubiquitinated forms

• Transfer conditions:

  • 100V for 60-90 minutes in wet transfer systems

  • Semi-dry transfer at 25V for 30 minutes also effective

• Blocking and antibody dilution:

  • 5% non-fat milk in TBST (preferred over BSA for reduced background)

  • Primary antibody dilutions typically 1:1000-1:2000

  • Overnight incubation at 4°C improves specific signal

• Detection method:

  • ECL-based chemiluminescence provides sufficient sensitivity for most applications

  • Fluorescent secondary antibodies allow multiplex detection with other proteins

How should researchers troubleshoot poor signal-to-noise ratios when using RPS7A antibodies?

Common challenges and solutions when using RPS7A antibodies include:

• High background issues:

  • Increase washing duration and frequency (5-6 washes, 10 minutes each)

  • Use alternative blocking agents (switch between milk, BSA, commercial blockers)

  • Pre-adsorb antibody with cell lysate from non-expressing cells

• Weak specific signal:

  • Optimize antibody concentration with titration experiments

  • Increase protein loading (typical range 20-50 μg of total protein)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use signal enhancement systems (biotin-streptavidin amplification)

• Multiple bands detection:

  • Verify if bands represent ubiquitinated forms (use deubiquitinase inhibitors)

  • Compare with CRISPR knockout samples to identify specific bands

  • Use antibodies targeting different epitopes to confirm band patterns

• Inconsistent results:

  • Standardize lysate preparation methods

  • Implement quantitative loading controls

  • Consider batch effects of antibodies and prepare working aliquots

How can RPS7A antibodies be integrated with other -omics approaches?

Modern multi-omics strategies can be enhanced with RPS7A antibodies:

• Integrating with transcriptomics:

  • RIP-seq combines RPS7A immunoprecipitation with RNA sequencing to identify all RNA targets

  • CLIP-seq (cross-linking immunoprecipitation) provides nucleotide-resolution binding sites

• Combining with proteomics:

  • IP-MS (immunoprecipitation with mass spectrometry) identifies RPS7 protein interaction networks

  • Proximity labeling (BioID-RPS7 fusion) captures transient interactions

• Integration with functional genomics:

  • ChIP-seq to investigate potential chromatin associations of RPS7

  • CRISPR screens combined with RPS7A antibody-based phenotyping

Research has successfully employed RNA-seq and RIP approaches to identify LOXL2 as a critical RNA target of RPS7 in hepatocellular carcinoma, demonstrating the power of integrating antibody-based techniques with -omics approaches .

What quantitative approaches can measure RPS7 post-translational modifications?

Quantifying RPS7 post-translational modifications (PTMs) requires specialized techniques:

• Site-specific PTM quantification:

  • Phospho-specific or ubiquitin-specific RPS7 antibodies

  • Mass spectrometry-based quantification of modified peptides

  • Parallel reaction monitoring (PRM) for specific modified sites

• Ubiquitination analysis:

  • Use of K48- vs K63-linkage specific antibodies to distinguish ubiquitin chain types

  • DUB treatment controls to confirm ubiquitin signals

  • Ubiquitin remnant profiling after trypsin digestion

• Dynamic PTM measurements:

  • Pulse-chase experiments with metabolic labeling

  • Time-course analysis after stimulus application

  • Inhibitor studies targeting specific modifying enzymes

Research has demonstrated that Not4 mediates monoubiquitination of RPS7/eS7A, while Hel2 facilitates subsequent polyubiquitination, particularly at lysine residues K72, K76, K83, and K84 . Quantitative analysis of these modifications provides insight into mRNA quality control efficiency.

How might RPS7A antibodies contribute to therapeutic development?

Emerging therapeutic applications involving RPS7A antibodies include:

• Cancer biomarker development:

  • Detection of RPS7 levels or specific PTM patterns as prognostic indicators

  • Monitoring RPS7-LOXL2-ITGB1 pathway activity in HCC progression

  • Assessment of treatment response through RPS7 pathway alterations

• Targeted therapy approaches:

  • Antibody-drug conjugates targeting surface-exposed RPS7 in certain cancer types

  • Small molecule screening using RPS7 antibody-based readouts

  • Inhibition of RPS7-RNA interactions as a therapeutic strategy

• RNA quality control modulation:

  • Targeting the RPS7 ubiquitination pathway to enhance degradation of aberrant mRNAs

  • Modifying NGD pathway efficiency through RPS7-related mechanisms

Research suggests that the RPS7/LOXL2/ITGB1 axis may represent a novel therapeutic target for HCC treatment, with potential applications in preventing metastasis .

What role might RPS7A antibodies play in understanding ribosomopathies?

RPS7A antibodies can provide insights into ribosomopathies (diseases caused by ribosomal protein defects):

• Diamond-Blackfan Anemia (DBA) research:

  • RPS7 mutations (DBA8) cause a subset of Diamond-Blackfan Anemia cases

  • Antibodies can help characterize mutant RPS7 expression, localization, and function

• Ribosome assembly analysis:

  • Tracking RPS7 incorporation into pre-ribosomal complexes in health and disease

  • Comparing wild-type versus mutant RPS7 assembly dynamics

• Stress response characterization:

  • Monitoring RPS7 behavior during ribotoxic stress

  • Evaluating interactions with stress response factors

• Translational fidelity assessment:

  • Investigating how RPS7 variants affect translation accuracy and efficiency

  • Correlating RPS7 PTMs with translational output

These approaches can help elucidate the complex relationship between ribosomal protein defects and the tissue-specific manifestations observed in ribosomopathies .